BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients
- First Posted Date
- 2009-02-19
- Last Posted Date
- 2013-06-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 30
- Registration Number
- NCT00847314
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
Phase 2
Terminated
- Conditions
- Overactive DetrusorMultiple Sclerosis
- Interventions
- First Posted Date
- 2009-02-18
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT00845338
ODiXahip - a Phase IIa Dose Escalating Proof of Principle Trial
Phase 2
Completed
- Conditions
- PreventionThromboembolism
- Interventions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2014-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 641
- Registration Number
- NCT00839826
Oral Direct Factor Xa Inhibitor BAY59-7939 in Patients With Acute Symptomatic Proximal Deep Vein Thrombosis(ODIXa-DVT)
Phase 2
Completed
- Conditions
- Venous ThrombosisDeep Vein Thrombosis
- Interventions
- Drug: Xarelto (Rivaroxaban, BAY59-7939)Drug: Enoxaparin/Vitamin K-Antagonist
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2023-09-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 613
- Registration Number
- NCT00839163
Efficacy of Dexpanthenol in Thermic Erythema
Phase 2
Completed
- Conditions
- Erythema
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2013-10-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 55
- Registration Number
- NCT00839462
Moisturizing Effect of Two Dexpanthenol Formulations
Phase 2
Completed
- Conditions
- Skin Abnormalities
- Interventions
- First Posted Date
- 2009-02-09
- Last Posted Date
- 2014-10-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT00839280
Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis
Completed
- Conditions
- HypogonadismParaplegiaBone DensityOsteoporosis
- Interventions
- First Posted Date
- 2009-02-06
- Last Posted Date
- 2010-04-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00838838
Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty
Completed
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: Standard care treatment for VTE prophylaxisDrug: Rivaroxaban (Xarelto, BAY59-7939)
- First Posted Date
- 2009-01-29
- Last Posted Date
- 2017-01-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19076
- Registration Number
- NCT00831714
A Study to Assess Efficacy and Safety of IV/PO Moxifloxacin in the Treatment of cSSSIs
Phase 3
Completed
- Conditions
- Infectious Diseases
- Interventions
- Drug: Avelox (Moxifloxacin, BAY12-8039)Drug: Amoxicilline/clavulanic
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 16
- Registration Number
- NCT00828971
Hepatic Impairment Study
- First Posted Date
- 2009-01-26
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00829231
Β© Copyright 2025. All Rights Reserved by MedPath